Intellectual Property and Government-Funded Research: Navigating the Bayh-Dole Framework

For many life sciences startups, particularly those that have emerged from academic research environments or that are pursuing early-stage science in areas of significant public health interest, government funding is a critical source of capital. Grants from the National Institutes of Health, the National Science Foundation, the Department of Defense, and other federal agencies provide resources that allow startups and their academic collaborators to advance research that might otherwise be too early or too speculative to attract private investment. However, government funding comes with a set of legal obligations that directly affect how intellectual property arising from that funding can be owned, managed, and commercialized — and failing to understand and comply with these obligations can have serious consequences for a startup’s IP position and its ability to attract subsequent private investment. The foundation of this regulatory framework in the United States is a federal statute known as the Bayh-Dole Act and understanding how it works is an essential part of managing IP in any research collaboration that involves federal funding.

The Bayh-Dole Act: What It Is and Why It Matters

Before the Bayh-Dole Act was enacted in 1980, inventions arising from federally funded research were generally owned by the federal government, which meant that universities and their researchers had little incentive to commercialize their discoveries and private companies had limited ability to obtain the exclusive licenses necessary to justify the investment required to bring new products to market. The result was an enormous repository of publicly funded science that went largely unexploited commercially. The Bayh-Dole Act fundamentally changed this dynamic by allowing universities, small businesses, and non-profit institutions to retain ownership of inventions made with federal funding, provided they comply with a defined set of obligations designed to ensure that the public benefits from the investment it has made. The impact of the Act on the commercialization of academic research has been profound — it is widely credited with catalyzing the modern biotechnology industry and enabling the university-to-startup pathway that has become a central feature of the life sciences innovation ecosystem. For a startup operating within this ecosystem, whether as a direct recipient of federal funding or as a licensee of technology developed under federal funding at a university, Bayh-Dole creates both opportunities and obligations that must be actively managed.

Key Obligations Under Bayh-Dole

The Bayh-Dole Act imposes several specific obligations on institutions and companies that receive federal funding and make inventions arising from that funding. The first and most fundamental is the obligation to disclose any invention arising from federally funded research to the funding agency within a defined timeframe — typically two months from the time the invention is reported to the institution’s technology transfer office. Failure to make timely disclosure can result in the loss of rights to the invention. The second obligation is to elect title to the invention — that is, to formally assert ownership — within a defined period following disclosure. If the institution or company does not elect title, the government retains the right to do so. Once title has been elected, the institution or company must file a patent application within one year and take steps to commercialize the invention, which in practice means actively seeking licensing partners or developing the technology internally. Throughout this process, the funding agency must be kept informed of the status of the patent application and the commercialization efforts.

The Government’s Retained Rights: March-In and License Rights

Even when a startup or institution properly elects title to a federally funded invention under Bayh-Dole, the federal government retains two significant rights that every life sciences startup needs to understand. The first is a royalty-free, non-exclusive license to practice the invention for government purposes — meaning that the government can use the technology for its own needs without paying royalties, regardless of who holds the patent. This right is generally not commercially disruptive in most life sciences contexts, but it is a permanent encumbrance on the patent that will be disclosed in due diligence and that sophisticated investors and acquirers will scrutinize. The second and more consequential retained right is the government’s march-in right — the authority, under defined circumstances, to require the patent holder to grant a license to a third party, or to grant such a license itself, if the patent holder has failed to take effective steps to achieve practical application of the invention, if action is necessary to alleviate health or safety needs, or if the invention is not being made available to the public on reasonable terms. March-in rights have been the subject of significant controversy in the pharmaceutical industry, particularly in debates about drug pricing, and while the government has never formally exercised march-in rights solely on the basis of high drug prices as of the time of this writing, the existence of this authority is a factor that investors in companies with significant Bayh-Dole encumbered assets will consider carefully.

Identifying and Disclosing Government Funding Obligations

One of the most common and consequential IP problems that arises in life sciences due diligence is the discovery of undisclosed government funding obligations attached to patents that a startup believed it owned free and clear. This situation arises more often than might be expected for several reasons. Research collaborations between startups and universities are common, and the university’s work on a project may be supported by federal grants that the startup’s founders are not fully aware of. Academic founders may have continued to receive federal funding through their university laboratory while simultaneously developing technology that was being transferred to their startup. A graduate student or postdoctoral fellow who joins a startup and contributes inventions may have developed foundational ideas while working on a federally funded project at their previous institution. In each of these scenarios, the federal funding creates Bayh-Dole obligations that attach to the resulting inventions, and a failure to identify, disclose, and comply with those obligations can result in a loss of patent rights or a requirement to grant licenses that significantly diminish the value of the IP. Every startup should conduct a systematic audit of the funding sources underlying its core technology — tracing not just its own funding history but that of its academic collaborators and founding team members — and should work with counsel experienced in Bayh-Dole compliance to identify and address any obligations that exist.

Small Business Innovation Research and Small Business Technology Transfer Programs

Two federal funding programs deserve particular attention for life sciences startups: the Small Business Innovation Research program, known as SBIR, and the Small Business Technology Transfer program, known as STTR. These programs provide grant and contract funding specifically to small businesses engaged in research and development with commercial potential, and they are among the most important sources of non-dilutive early-stage capital available to life sciences startups. SBIR funding is awarded directly to small businesses, while STTR funding requires a formal collaboration between a small business and a research institution such as a university or federal laboratory, with a defined portion of the work performed by the research partner. Both programs are structured in phases — Phase I awards provide relatively modest funding to establish the feasibility of a concept, while Phase II awards provide larger amounts to advance development toward commercialization — and both carry Bayh-Dole obligations with respect to inventions arising from the funded work. Importantly, SBIR and STTR awardees retain ownership of IP arising from their awards, subject to the government’s retained license and march-in rights, and they are required to prioritize U.S. manufacturing in the commercialization of products developed with program funds — a requirement that can have implications for supply chain and licensing strategy that should be considered before accepting an award.

Collaboration Agreements with Government Laboratories

Beyond grant funding, life sciences startups sometimes enter into collaborative research arrangements directly with federal laboratories — institutions such as the National Laboratories operated by the Department of Energy, or the research facilities of the National Institutes of Health itself. These arrangements, typically structured as Cooperative Research and Development Agreements known as CRADAs, allow startups to access the unique scientific capabilities, equipment, and expertise of federal laboratories while sharing in the IP that results from the collaboration. CRADAs are governed by their own IP framework, which differs in important respects from the Bayh-Dole framework applicable to grant funding. Under a CRADA, the federal laboratory and the private partner negotiate the ownership and licensing of jointly developed IP as part of the agreement itself, and the terms can be structured to give the private partner exclusive licensing rights to inventions arising from the collaboration — a significant advantage compared to the more constrained IP rights available under standard grant funding. However, CRADAs also require careful negotiation of publication rights, confidentiality obligations, and the scope of the collaboration, and the process of finalizing a CRADA with a federal laboratory can be time-consuming. Startups that have the opportunity to enter into a CRADA with a laboratory whose capabilities are directly relevant to their development program should approach the negotiation with experienced counsel and a clear understanding of the IP terms they need to make the collaboration commercially worthwhile.

Strategic Considerations for Government-Funded IP

For a life sciences startup, the decision to pursue government funding — and the management of the IP obligations that come with it — should be approached as a strategic business decision rather than purely a financial one. Non-dilutive government funding is extraordinarily valuable, particularly in the earliest stages of development when the cost of private capital is highest and the ability to advance the science without giving up equity is most beneficial. At the same time, the obligations that attach to government-funded IP are permanent encumbrances that will follow the technology through every subsequent transaction — licensing deals, partnerships, and acquisitions alike — and that must be disclosed and managed throughout the life of the patent. Startups that maintain meticulous records of their funding sources, comply scrupulously with disclosure and filing obligations, and proactively address Bayh-Dole compliance as part of their IP management practice will find that government funding is a powerful tool that strengthens rather than complicates their commercial position. Those that treat compliance as an afterthought, or that discover government funding obligations for the first time in the middle of a due diligence process, will face a far more difficult and costly remediation challenge. As with so many aspects of IP management, the time to get this right is before a problem arises — and the investment in doing so is modest compared to the consequences of getting it wrong.

This article is part of our Life Sciences Startup IP Resource Center.